catalym
Posted by catalym
January 4, 2023
January 4, 2023

J.P. Morgan '23

January 9-12, 2023

Read More
catalym
Posted by catalym
January 4, 2023
January 4, 2023

BioEurope Spring '23

March 20-22, 2023

Read More
catalym
Posted by catalym
January 4, 2023
January 4, 2023

AACR '23

April 13-19, 2023

Read More
catalym
Posted by catalym
January 4, 2023
January 4, 2023

ASCO '23

June 2-6, 2023

Read More
catalym
Posted by catalym
January 4, 2023
January 4, 2023

BIO '23

June 5-9, 2023

Read More
catalym
Posted by catalym
December 14, 2022
catalym
Posted by catalym
November 22, 2022
catalym
Posted by catalym
September 26, 2022
September 26, 2022

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...

Read More
catalym
Posted by catalym
September 10, 2022
September 10, 2022

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination

CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...

Read More
catalym
Posted by catalym
September 5, 2022
WordPress Cookie Notice by Real Cookie Banner